Search Result

Results for "

endogenous ceramide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Endogenous Metabolite (10) Acyltransferase (1) Caspase (1) Ceramidase (1) Drug Intermediate (7) Fluorescent Dye (1) iGluR (1) Isotope-Labeled Compounds (7) Liposome (1) Mitochondrial Metabolism (1) Mitophagy (1) PARP (1) PINK1/Parkin (1) Reference Standards (1) Telomerase (1)
By Research Areas:	Cancer (3) Endocrinology (1) Inflammation/Immunology (2) Metabolic Disease (9) Neurological Disease (4)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Endogenous Metabolite

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124177A

C14 Ceramide (d18:1/14:0)	Endogenous Metabolite	Neurological Disease Metabolic Disease
C14 Ceramide (d18:1/14:0) is an endogenous ceramide produced by ceramide synthetase 6, which can be used for Parkinson's and diabetes research .

HY-126015

P053 1 Publications Verification	Acyltransferase	Metabolic Disease
P053 is a potent, non-competitive and selective ceramide synthase 1 (CerS1) inhibitor wirh an IC₅₀ of 0.5 μM. P053 acts as an endogenous inhibitor of mitochondrial fatty acid oxidation in muscle. Whole-body adiposity regulator .

HY-154831

C22-Ceramide N-Behenoyl-D-erythro-sphingosine; Cer d18:1/22:0	Liposome	Metabolic Disease
C22-Ceramide (Cer d18:1/22:0) is an endogenous bioactive sphingolipid. C22-Ceramide reduces the propensity of C16-ceramide channel formation in isolated rat liver mitochondria and in liposomes .

HY-113679

Ceramides Mixture 2 Publications Verification	Telomerase	Metabolic Disease Endocrinology
Ceramides Mixture is an endogenous ceramide and consists of hydroxy and non-hydroxy fatty acid-containing ceramides. Ceramides Mixture is a main lipid component of the permeability barrier in epidermis. Ceramides Mixture is involved in the regulation of growth inhibition, cell cycle arrest, and modulation of telomerase activity .

HY-N10634

D-Glucosyl-β-1,1′-N-palmitoylsphingosine C16 Glucosyl(β) ceramide (d18:1/16:0)	Others	Inflammation/Immunology
D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity .

HY-124962

D-NMAPPD 1 Publications Verification (1R,2R)-B13	iGluR	Neurological Disease Cancer
D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor. D-NMAPPD regulates NMDA receptor properties by enhancing endogenous production of ceramides. D-NMAPPD has anticancer effecs .

HY-124177AS

C14 Ceramide (d18:1/14:0)-d7	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Metabolic Disease
C14 Ceramide (d18:1/14:0)-d₇ is the deuterium labeled C14 Ceramide (d18:1/14:0) (HY-124177A). C14 Ceramide (d18:1/14:0) is an endogenous ceramide produced by ceramide synthetase 6, which can be used for Parkinson's and diabetes research .

HY-124134

AD-2646 LCL102	Ceramidase Caspase PARP	Cancer
AD-2646 (LCL102), a ceramide analog, can kill leukemic T cells (EC₅₀: 40 μM). AD-2646 triggers the cleavage of caspase-8, -9 and -3, as well as the caspase substrate PARP. AD-2646 is a ceramidase inhibitor. AD-2646 induces an accumulation of endogenous ceramide owing to perturbed ceramide metabolism .

HY-172668

C22 Ceramide (d18:1(14Z)/22:0)	Endogenous Metabolite	Others
C22 Ceramide (d18:1(14Z)/22:0) is an endogenous bioactive sphingolipid. C22 Ceramide (d18:1(14Z)/22:0) has the effects of promoting cell cycle arrest and inducing apoptosis .

HY-176568

LCL768	Mitophagy PINK1/Parkin Mitochondrial Metabolism	Neurological Disease Cancer
LCL768 is a ceramide analog. LCL768 attenuates PARKIN succination to promote PARKIN activation and mitophagy. LCL768 induces CerS1-mediated endogenous C18-ceramide accumulation in mitochondria to mediate mitophagy, which is dependent on DRP1 activation via nitrosylation at C644. LCL768 alters mitochondrial metabolism, resulting in fumarate depletion and leading to tumor suppression. LCL768 improves sensorimotor defects in neurodegenerative diseases like ALS .

HY-D1574

C6 NBD Sphingomyelin	Fluorescent Dye	Others
C6 NBD Sphingomyelin is a fluorescent short-chain analogue of Sphingomyelin (HY-113498). Chlamydia trachomatis acquires C6 NBD Sphingomyelin endogenously synthesizes from C6-NBD-ceramide and transportes to the chlamydial inclusion. C6 NBD Sphingomyelin can incorporate into the plasma membrane .

HY-128753

D-Lyxose	Endogenous Metabolite Drug Intermediate	Metabolic Disease
D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S6

D-Lyxose-d	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Metabolic Disease
D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S7

D-Lyxose-d-1	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Metabolic Disease
D-Lyxose-d-1 is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S3

D-Lyxose-13C-2	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Others
D-Lyxose- ¹³C-2 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S5

D-Lyxose-13C-4	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Others
D-Lyxose- ¹³C-4 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753R

D-Lyxose (Standard)	Reference Standards Endogenous Metabolite Drug Intermediate	Metabolic Disease
D-Lyxose (Standard) is the analytical standard of D-Lyxose. This product is intended for research and analytical applications. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S4

D-Lyxose-13C-3	Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate	Others
D-Lyxose- ¹³C-3 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-N10634S

D-Glucosyl-β-N-palmitoylsphingosine-d3 N-ω-CD₃-Hexadecaoyl-glucopsychosie; GluCe(d18:1/16:0-d₃); Glucosylceamide-d₃ (d18:1/16:0-d3)	Isotope-Labeled Compounds Others	Inflammation/Immunology
D-Glucosyl-β-N-palmitoylsphingosine-d₃ (N-ω-CD₃-Hexadecaoyl-glucopsychosie) is deuterium labeled D-Glucosyl-β-1,1′-N-palmitoylsphingosine (HY-N10634). D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity .

Cat. No.	Product Name	Type

HY-D1574

C6 NBD Sphingomyelin	Fluorescent Dyes/Probes
C6 NBD Sphingomyelin is a fluorescent short-chain analogue of Sphingomyelin (HY-113498). Chlamydia trachomatis acquires C6 NBD Sphingomyelin endogenously synthesizes from C6-NBD-ceramide and transportes to the chlamydial inclusion. C6 NBD Sphingomyelin can incorporate into the plasma membrane .

Cat. No.	Product Name	Type

HY-154831

C22-Ceramide N-Behenoyl-D-erythro-sphingosine; Cer d18:1/22:0	Drug Delivery
C22-Ceramide (Cer d18:1/22:0) is an endogenous bioactive sphingolipid. C22-Ceramide reduces the propensity of C16-ceramide channel formation in isolated rat liver mitochondria and in liposomes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10634

D-Glucosyl-β-1,1′-N-palmitoylsphingosine C16 Glucosyl(β) ceramide (d18:1/16:0)	Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Others
D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity .

HY-128753

D-Lyxose	Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides	Endogenous Metabolite Drug Intermediate
D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753R

D-Lyxose (Standard)	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite Saccharides	Reference Standards Endogenous Metabolite Drug Intermediate
D-Lyxose (Standard) is the analytical standard of D-Lyxose. This product is intended for research and analytical applications. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

Cat. No.	Product Name	Chemical Structure

HY-124177AS

C14 Ceramide (d18:1/14:0)-d7
C14 Ceramide (d18:1/14:0)-d₇ is the deuterium labeled C14 Ceramide (d18:1/14:0) (HY-124177A). C14 Ceramide (d18:1/14:0) is an endogenous ceramide produced by ceramide synthetase 6, which can be used for Parkinson's and diabetes research .

HY-128753S6

D-Lyxose-d
D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

D-Lyxose-d

D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S7

D-Lyxose-d-1
D-Lyxose-d-1 is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

D-Lyxose-d-1

D-Lyxose-d-1 is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S3

D-Lyxose-13C-2
D-Lyxose- ¹³C-2 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

D-Lyxose-13C-2

D-Lyxose- ¹³C-2 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S5

D-Lyxose-13C-4
D-Lyxose- ¹³C-4 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

D-Lyxose-13C-4

D-Lyxose- ¹³C-4 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-128753S4

D-Lyxose-13C-3
D-Lyxose- ¹³C-3 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

D-Lyxose-13C-3

D-Lyxose- ¹³C-3 is the ¹³C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .

HY-N10634S

D-Glucosyl-β-N-palmitoylsphingosine-d3
D-Glucosyl-β-N-palmitoylsphingosine-d₃ (N-ω-CD₃-Hexadecaoyl-glucopsychosie) is deuterium labeled D-Glucosyl-β-1,1′-N-palmitoylsphingosine (HY-N10634). D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks